AsianScientist (Oct. 10, 2013) – PAREXEL International Corporation, a global biopharmaceutical services provider, has launched a new service called PAREXEL Dĭng Huī, China Trials Solution.
Designed to support clients’ drug development objectives in China, the service combines advanced technology and international standard operating procedures with local expertise and resources, in order to deliver cost-effective services that meet global quality standards.
“PAREXEL Dĭng Huī brings world-class, quality service to Chinese clinical registration trials by combining on-the-ground expertise, innovation and technology. This can help enable clients to bring new drugs to patients in this important market,” said Albert Liou, Vice Chairman of PAREXEL International Co. Limited, a subsidiary of PAREXEL International Corporation.
PAREXEL Dĭng Huī will support clients through locally delivered, streamlined services that support single-country registration trials and are tailored to meet Chinese Non-Disclosure Agreements (NDA) submission requirements.
“PAREXEL Dĭng Huī reflects an evolution of our overall business model to address country-specific clinical development needs for clients who are seeking to launch products in China,” said Mark A. Goldberg, M.D., President and Chief Operating Officer of PAREXEL. “We believe this focused offering will deliver important benefits in terms of cost effectiveness and efficiency in a complex, rapidly growing market.”
——
Source: PAREXEL.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
